NEW YORK--(BUSINESS WIRE)--WallStAnalyst.com (SEBI Reg. # INH200000147) (www.wallstanalyst.com) published this week’s ‘Weekly Screener’ to our members and the retail investor community following two weeks of erratic global market environment. At the end of the session on Friday, the iShares NASDAQ Biotechnology exchange traded fund, a $7.9 billion fund, declined the most in a day since April 2014. Our weekly screener looks at the top gainers, top losers, and most volatile stocks in the biotech industry with the following companies receiving coverage from our analysts: Opko Health Inc. (NYSE: OPK), Geron Corporation (NASDAQ: GERN), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Agenus Inc. (NASDAQ: AGEN) and Prima Biomed Ltd. (NASDAQ: PBMD). Visit us for your free biotech stocks coverage at:
Last Friday, the S&P 500 closed lower at 1,931.34 and booked a 1.4% weekly loss. The Dow Jones Industrial Average DJIA had been up by as many as 250 points, and closed 113.35 points, or 0.7%, higher, at 16,314.67. The NASDAQ Composite ended the day down 47.98 points, or 1%, at 4,686.50 and posted a 2.9% weekly loss. The iShares NASDAQ Biotechnology ETF, which measures the performance of 144 NASDAQ-listed biotech firms, plunged 5.1%. Register now for our complimentary analysis on why the markets and the biotech sector have been under pressure at:
The U.S., which accounts for about 40% of global sales, is considered to be the most lucrative area in the world when it comes to medicines sales. In light of recent developments in the industry, WallStAnalyst.com’s analysts will be monitoring some key equities and the sector as a whole. Sign up for our free coverage at:
The information within this report is provided to its recipients for informational purposes only and shall not be used or considered as an offer or solicitation to trade or subscribe for securities or other financial instruments. The data contained within this report is based on information derived from reliable sources, but its accuracy or completeness cannot be warranted, expressly or impliedly, by WallStAnalyst.com.